skip to Main Content

Stem Cell Therapeutics Merger, Technology Featured in Biotechnology Focus

Dr. Aaron Schimmer, University Health Network
Dr. Aaron Schimmer of the University Health Network discovered that Tigecycline was effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.

The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.

Here’s a quote from Lawrence’s article:

“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs with known safety profiles can significantly lower the risk in the drug development process, saving time and cost,” says Dr. Niclas Stiernholm, president and CEO of Stem Cell Therapeutics Corp.”

Continue Reading

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp. logo
Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.

The agreement provides Stem Cell Therapeutics (“SCT”) with an option to an exclusive world-wide license to an innovative cancer stem cell program.

This agreement produced a license for a UHN technology on April 17, 2013.

Continue Reading
Back To Top